ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S: Financial statements 2015
CVR: 32323502
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S (CVR 32323502) has filed annual accounts for 2015. In 2015, the company reported a gross profit of EUR 5,370,361 and a net result of EUR 5,606,878 compared with EUR 5,786,449 the year before. That is a decrease of 1.6% compared with the year before. Equity in the 2015 report amounted to EUR 10,857,730. The solvency ratio was 77.9%.
- Gross Profit
- EUR 5,370,361
- Profit/Loss
- EUR 5,606,878
- Equity
- EUR 10,857,730
- Total Assets
- EUR 13,935,811
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | - | 5.4M EUR | 5.6M EUR | 10.9M EUR | - |
| 2014 | - | 5.5M EUR | 5.8M EUR | 5.3M EUR | - |
| 2013 | - | 18.5M | 16.3M | 19.1M | - |
Official annual report
How creditworthy is ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S has published its annual report for 2014. Gross profit came to DKK 5,456,890, and the net result was DKK 5,786,449.
About ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S
ASCENDIS PHARMA, OPHTHALMOLOGY DIVISION A/S is a Danish company of the type Aktieselskab based in Hellerup, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named ACP 30.06.2012 1 A/S. The management consists of Jan Møller Mikkelsen. The board consists of Michael Wolff Jensen (chair), Anni Lotte Kirstine Pedersen and Jan Møller Mikkelsen. The company is owned by ASCENDIS PHARMA A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of EUR 5,567,000 and a net result of EUR -5,238,000 compared with EUR 5,001,000 the year before. Equity in the 2025 report amounted to EUR -38,639,000.
